279 results
8-K
LFCR
Lifecore Biomedical Inc
16 May 24
Lifecore Biomedical Completes Incremental Liquidity Initiatives
4:48pm
to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause
8-K
EX-10.1
LFCR
Lifecore Biomedical Inc
14 May 24
Entry into a Material Definitive Agreement
5:04pm
offset, defense or counterclaim of any kind, nature or description whatsoever. (b) Acknowledgement of Loan Documents. The Loan Parties hereby acknowledge … , disputes, causes, damages, actions and causes of actions (whether at law or in equity) and obligations of every nature whatsoever, whether liquidated
8-K
LFCR
Lifecore Biomedical Inc
14 May 24
Entry into a Material Definitive Agreement
5:04pm
on information currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks
8-K
LFCR
Lifecore Biomedical Inc
19 Apr 24
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
4:34pm
and expectations regarding future events, which in turn are based on information currently available to the Company. By their nature, forward-looking statements
8-K
EX-10.3
LFCR
Lifecore Biomedical Inc
20 Mar 24
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
6:32pm
to any further payment from the Company of any nature (including attorneys’ fees and costs incurred).
(b)Executive is the sole and lawful owner of all
8-K
EX-10.2
f39ly2h
20 Mar 24
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
6:32pm
8-K
z5qgxp1dpigwam
12 Jan 24
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
4:51pm
8-K
EX-10.2
1wq5n
5 Jan 24
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-10.3
1bbavef
5 Jan 24
Entry into a Material Definitive Agreement
4:09pm
8-K
b8btvy
31 Oct 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
6:17am
8-K
mumnl2i1 c0smi
18 Oct 23
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
4:07pm
8-K
b25u 6zwza8vgtrnys
22 Aug 23
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
4:11pm
8-K
EX-10.6
l99h hbtx4qe1ep
22 May 23
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan
9:57pm
8-K
EX-10.3
3t439m
22 May 23
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan
9:57pm
8-K
EX-10.1
nto3s5
22 May 23
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan
9:57pm